Who Paid My Doc
Marla Dubinsky
New York, NY Medical Doctor
NPI 1790741718 CMS profile 80775
1 Gustave L Levy Pl, Box 1134, New York, NY 10029
General payments
$1,351,136
Research payments
$180,950
Ownership & investment interest
$0
Research they led as principal investigator
$4,770
Through program year 2025, Marla Dubinsky of New York, NY is reported in the CMS Open Payments database as having received $1,351,136 across 730 general payments and $180,950 in research payments paid to them. Separately, studies naming them as principal investigator received $4,770 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
13 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $228,096 | 118 | |
| 2025 | Research | $39,610 | 26 | |
| 2024 | General | $343,512 | 162 | |
| 2024 | Research | $29,590 | 25 | |
| 2023 | General | $244,868 | 127 | |
| 2023 | Research | $34,390 | 37 | |
| 2022 | General | $144,666 | 109 | |
| 2022 | Research | $38,660 | 37 | |
| 2021 | General | $137,025 | 57 | |
| 2021 | Research | $15,860 | 18 | |
| 2020 | General | $123,067 | 45 | |
| 2020 | Research | $22,840 | 15 | |
| 2019 | General | $129,902 | 112 |
Beside peers
- Marla Dubinsky
- New York median
- Middle half of New York
- National median
In program year 2025, general payments to Marla Dubinsky were reported at $228,096. Among 69,423 New York profiles paid that year, the median was $180 and the middle half received between $58 and $640.
Show as a table
| Year | Marla Dubinsky | New York median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $129,902 | $175 | $53–$665 | $163 |
| 2020 | $123,067 | $122 | $37–$426 | $114 |
| 2021 | $137,025 | $144 | $44–$514 | $132 |
| 2022 | $144,666 | $160 | $51–$578 | $149 |
| 2023 | $244,868 | $170 | $54–$593 | $160 |
| 2024 | $343,512 | $173 | $56–$618 | $164 |
| 2025 | $228,096 | $180 | $58–$640 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
888 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.